Sponsors (7)
This resolution increases federal visibility and awareness of rare diseases and related NIH/FDA programs—potentially benefiting patients and advocacy—but is symbolic and may raise expectations or imply future spending without committing concrete solutions or funding.
People with rare diseases: federal recognition highlights NIH and FDA programs that could help speed development and availability of treatments.
Patients and families: formally recognizing Rare Disease Day and noting prevalence raises public awareness, which can increase advocacy, support, and resources for affected families.
Patients: the resolution highlights diagnostic and financing challenges but does not propose concrete remedies, which may raise hopes without delivering solutions.
Taxpayers and budget holders: emphasizing federal programs and anniversaries may imply further federal focus or spending on rare disease initiatives, creating potential fiscal implications.
Based on analysis of 2 sections of legislative text.
States congressional findings about rare diseases, defining them, noting prevalence and treatment gaps, and recognizing federal programs and Rare Disease Day.
Declares congressional findings about rare diseases, including a definition (fewer than 200,000 people in the U.S.), estimated prevalence, the large treatment gap, and related federal programs and observances. Notes that many rare diseases are serious or life‑threatening, that children make up a significant portion of those affected, and that most rare diseases lack FDA‑approved treatments despite existing orphan drug approvals and federal research efforts. Recognizes the upcoming 42nd anniversary of the Orphan Drug Act and notes federal efforts such as FDA and NIH programs, financial and diagnostic challenges for patients, and the annual observance of Rare Disease Day on the last day of February.
Introduced February 27, 2025 by John A. Barrasso · Last progress February 27, 2025